TSHA vs BCAT Comparison

Taysha Gene Therapies Inc is a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system, or CNS. The company's clinical program TSHA-102 is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. The Company views its operations and manages its business as a single operating segment, the gene therapy segment, which is the business of developing AAV-based gene therapies for the treatment of rare monogenic diseases of the central nervous system.

BlackRock Capital Allocation Trust, now BlackRock Capital Allocation Term Trust, is a diversified, closed-end management investment company. Its investment objectives are to provide total return and income through a combination of current income, current gains, and long-term capital appreciation. The Trust invests in a portfolio of both equity and debt securities of companies from different sectors such as Information Technology, Financials, Industrials, Communication, Health Care, etc. It also utilizes an option-writing (selling) plan in an effort to generate current gains from option premiums and to enhance its risk-adjusted returns.